All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

GSK and FDA Agree on Consent Decree

May 5, 2005
By Pharmaceutical Technology Editors
News
Article

GSK and FDA Agree on Consent Decree

GlaxoSmithKline (GSK, London and Philadelphia) and the US Food and Drug Administration have reached an agreement on a consent decree regarding corrections at the company's Cidra, Puerto Rico, manufacturing facility.

GSK's Cidra plant manufactures the tablets—"Paxil CR" (paroxetinehydrochloride controlled release, for depression) and "Avandamet"(combination rosiglitazone maleate and metformin hydrochloride, fordiabetes)—seized by federal marshals at three locations lastFebruary. FDA had obtained the warrant, citing manufacturing errorsthat produced some tablets with out-of-specification levels of activeingredient.

In a preparedstatement, GSK said that it "has identified the source ofthe manufacturing issues related to both products, and has alreadyimplemented revisions to those manufacturing processes." GSK expects toresume manufacturing and distribution of Avandament and Paxil CR to theUnited States and elsewhere "in mid-year," well ahead of industry analysts'predictions.

The consent agreement also "requires that all corrections and thefirm's compliance with CGMP requirements be certified by a third-partyexpert," in addition to continuing FDA monitoring, according to FDA'sstatement. The agreement holds GSK to a well-defined procedure forreporting and correcting process shortcomings discovered during thisreview.

GSK will post a $650-million performance bond to ensure that theproduct seized in Feburary is "appropriately destroyed orreconditioned."  GSK says that it "anticipates meeting allrequirements of the bond within 90 days following entry of the decree."Although the proposed decree provides for penalties of up to $10 millionper year if the company does not hold to its terms, GSK emphasizes thatFDA is not imposing any fines or penalties at this time.

The draft consent decree was presented to the US District Court of theEastern District of North Carolina on April 27, and will take effectafter it is signed by GSK and FDA and entered by the court.

–Douglas McCormick

Recent Videos
Drug Digest: Patient Preference Drives Solid Dosage Trends
Behind the Headlines, Episode 17
Related Content

Data technology background. Abstract background. Connecting dots and lines on dark background. 3D rendering. 4k. | Image Credit: © Dmitry

Emerson Unveils AI Platform for Mission-Critical Industrial Applications

Christopher Cole
May 22nd 2025
Article

Emerson’s purpose-built industrial AI solutions are meant to enhance accessibility and reliability, enabling manufacturers to maximize efficiency and performance from automation systems.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics.  ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines.  ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.


A group of antibiotic pill capsules falling. Healthcare and medical 3D illustration background | Image Credit: © James Thew - stock.adobe.com

Personalised Capsule Machine Unveiled by ACG

Christopher Cole
May 20th 2025
Article

ACG partnered with Art of You to launch the world-first Personalised Capsule Machine, enabling on-demand, customized supplement capsules based on individual health data.

Related Content

Data technology background. Abstract background. Connecting dots and lines on dark background. 3D rendering. 4k. | Image Credit: © Dmitry

Emerson Unveils AI Platform for Mission-Critical Industrial Applications

Christopher Cole
May 22nd 2025
Article

Emerson’s purpose-built industrial AI solutions are meant to enhance accessibility and reliability, enabling manufacturers to maximize efficiency and performance from automation systems.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


·Mirai Bio and Thermo Fisher are partnering to integrate design, delivery, and CGMP manufacturing for nucleic acid-based therapeutics.  ·The collaboration will leverage Thermo Fisher’s RNA and advanced formulations facility to support scalable development of genetic medicines.  ·Mirai’s machine intelligence platform will be combined with Thermo Fisher’s technical and manufacturing expertise to streamline drug development workflows.

Mirai Bio and Thermo Fisher Partner to Advance Genetic Medicine Manufacturing

Christopher Cole
May 21st 2025
Article

Mirai Bio and Thermo Fisher partner to integrate AI-driven design with CGMP manufacturing, aiming to streamline development of genetic medicines.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Abnormal plasma cell or b-cell in multiple myeloma emitting paraprotein 3d illustration | Image Credit: © LASZLO - stock.adobe.com

CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib

Patrick Lavery
May 21st 2025
Article

Inobrodib is being developed as a first-in-class oral cancer drug that the company says will be able to treat not only multiple myeloma, but other specific cancers as well.


A group of antibiotic pill capsules falling. Healthcare and medical 3D illustration background | Image Credit: © James Thew - stock.adobe.com

Personalised Capsule Machine Unveiled by ACG

Christopher Cole
May 20th 2025
Article

ACG partnered with Art of You to launch the world-first Personalised Capsule Machine, enabling on-demand, customized supplement capsules based on individual health data.

About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.